Attending Biotech and Pharma
BOS non clinical 2009 is primarily a partnering event; a forum to connect biotech & pharma outsourcing executives with a network of specialist CROs operating at the discovery/development interface. In addition to 1 to 1 partnering we have organised a programme of speakers who will deliver perspective and experience from growing biotech, established pharma and the service sector.
We are pleased to announce a first class programme of speakers for BOS 2009 including the following experts in their fields; Dr Zoran Rankovic, Director Medicinal Chemistry, Schering-Plough will be opening proceedings by examining some of the trends shaping discovery within a pharma setting. Dr Wolfgang Ebenbeck, Flourine Team Leader at Saltigo GmbH will then outline their capabilities in flourine chemistry. Giving the biotech perspective at Discovery will be Dr Stephen Shuttleworth who will be looking at the approach at Karus Therapeutics to Lead Optimisation. Stephen is the Chief Scientific Officer at Karus. We are very pleased that Dr Andy Merritt who is Associate Director, Chemistry, Medical Council Research & Technology will be guiding the Discovery session as chair.
Kicking off the Early Discovery session will be Dr Chris Hobbs, Group Director of Chemistry at Proximagen Ltd. Following his participation in the inaugural BOS event in 2006 we are very pleased that Prof Hans-Jurgen Federsel, Director of Science, Global Process R&D, AstraZeneca will be participating again in BOS 2009 Prof Federsel is a leading international authority on process development and will give some of his insights into the trends shaping PR&D.
To close the 2009 programme we welcome Dr Andy Parsons, VP Head of Preclinical Development at the Center Excellence for External Drug Discovery (CEEDD), GlaxoSmithKline. This talk should give a valuable insight into how CEEDD work with their biotech collaboration partners and CROs to achieve R&D goals. This talk should also be very useful for biotech who are interested to learn more about how collaboration with a pharma partner would work in practice.
We hope you will agree it is a varied and interesting programme.
We hope that you will enjoy!
Bio2Business Team
| Provisional Programme: Biotech Outsourcing Strategies 2009: BOS non-clinical |
|
|---|---|
| 07.30 - 09.30 | Registration, Partnering & Breakfast |
| Optional - 09.00 - 09.30 | Opt in for: UK Trade and Investment Workshop
Internationalising your business: how the UK Government can help |
| 09.30 - 11.00 | Discovery Module
Chair: Dr Andy Merritt, Associate Director, Chemistry, Medical Research Council Technology |
| 09.30 - 10.00 | Creative solutions to attrition in pharmaceutical R&D
Dr Zoran Rankovic, Director, Medicinal Chemistry, Schering-Plough Research Institute |
| 10.00 - 10.30 | Fluorine Chemistry in Life Science R&D
Dr Michael Essers, Research and Development Manager, Saltigo, Key Sponsor |
| 10.30 - 11.00 | Small molecule lead discovery, optimisation and development in a semi-virtual R&D environment
Dr Stephen Shuttleworth, CSO, Karus Therapeutics |
| Optional - 11.00 - 11.30 | Opt in for: UK Trade and Investment Workshop
Unlocking the Framework 7 programme: accessing EU funding for business success |
| 11.00 - 11.30 | Coffee Break & Partnering |
| 11.30 - 12.30 | Technology Showcase
Chair: Dr Richard Todd, Director, CMOpharma Limited |
| 11.30 - 11.40 | Changing needs in high potency manufacturing
Dr Charlie Johnson, High Potency Business Manager, Carbogen Amcis AG |
| 11.40 - 11.50 | High-potency API manufacturing by Sochinaz
Dr Stanislas Veuthey, Business Development Manager, Sochinaz AG / Bachem |
| 11.50 - 12.00 | Avantium - steps ahead in solid state research
Pauline Jäger, VP Business Development, Avantium Technologies BV |
| 12.00 - 12.10 | Chirality, first-time-right
Dr Ton Vries, CEO, Syncom BV |
| 12.10 - 12.20 | Tools that Shasun Pharma Solutions use to aid process understanding
Steve Woolley, New Product Introduction Manager, Shasun Pharma Solutions Ltd |
| 12.20 - 12.30 | Questions and answers |
| 12.30 - 14.00 | Lunch & Partnering |
| Optional - 13.30 - 14.00 | Opt in for: Fulcrum Pharma Presentation
How Predictive are Animal Models for Clinical Development? |
| 14.00 - 15.30 | Early Development Module
Chair: Dr Rod Baker, Bioedge Pharma Consultancy Limited |
| 14.00 - 14.30 | Scale Up Strategies: Challenges and approaches to early development scale up of small molecules in a semi virtual biotech
Dr Chris Hobbs, Group Director of Chemistry, Proximagen Ltd |
| 14.30 - 15.00 | Development Focus: Current trends shaping process development
Prof Hans-Jürgen Ferdersel, Director of Science, Global Process R&D, AstraZeneca |
| 15.00 - 15.30 | The exploratory IND in preclinical development: Strategies for small molecule and large molecule R&D
Dr Penelope Ward, Chief Medical Officer, NovImmune |
| 15.30 - 16.00 | Coffee Break & Partnering |
| 16.00 - 17.00 | Case Study Module
Chair: Dr Lloyd Payne, Research Director, Aquapharm Biodiscovery Ltd |
| 16.00 - 16.45 | Collaboration between biotech, CROs and pharma to drive forward R&D and create win/win for all stake holders
Dr Andrew A Parsons, VP Head of Preclinical Development, Center Excellence for External Drug Discovery (CEEDD), GlaxoSmithKline |
| 17.00 Onwards | Drinks Reception: College Garden |
Key Sponsors
Gold CRO Sponsors
Silver CRO Sponsor
Exhibition Sponsor
Media Partner
